CP
FULC icon

Castleview Partners’s Fulcrum Therapeutics FULC Stock Holding History

Castleview Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.9K Buy
+19,100
New +$116K 0.03% 220

Other funds holding FULC

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Castleview Partners's FULC Position: Q2 2026 in Review

Castleview Partners opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 19,100 shares worth $69.9K. The stake represents 0.03% of the portfolio and ranks #220 among its holdings.

12 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Castleview Partners held 19,100 shares of Fulcrum Therapeutics worth $69.9K as of Q2 2026.
  • Fulcrum Therapeutics was a new Castleview Partners position in Q2 2026.
  • Fulcrum Therapeutics made up 0.03% of Castleview Partners's portfolio in Q2 2026, its #220 holding.
  • 12 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Castleview Partners's 13F filing for Q2 2026, filed 20 Jul 2026.